So first, we hope daraxonrasib gets approved. That’s the target, and that hopefully will happen at least in the United States very shortly, and I suspect around the world. In terms of what that means practically, more patients will have access to the drug. More people will be able to have access to this, hopefully, this potent drug. What it means for the field, I think, beyond that, is we need to start testing RAS inhibitors at every step of the way in pancreatic cancer...
So first, we hope daraxonrasib gets approved. That’s the target, and that hopefully will happen at least in the United States very shortly, and I suspect around the world. In terms of what that means practically, more patients will have access to the drug. More people will be able to have access to this, hopefully, this potent drug. What it means for the field, I think, beyond that, is we need to start testing RAS inhibitors at every step of the way in pancreatic cancer. Early-stage disease, locally advanced disease, resectable disease, all across the board. In fact, trials are already ongoing in all those aspects with combination, not just with daraxonrasib , but also with other KRAS inhibitors, allele-specific drugs, PAN RAS, you name it. So this is the avenue that we have to take over the next few years because that’s the avenue that will, in my opinion, produce the best results.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
